Evidence map›Paper›PMID 42226197›Full record

ArticleJournal of nanobiotechnology2026

Supramolecular coordination nanoplatform amplifies oxidative stress to overcome ferroptosis resistance in gallbladder cancer.

Yuhao Zhao, Jingyun Zhang, Chen Zhou, Mao Yang, Zhigang Zheng, Yixiang Gu, Yang Zhang, Xingqi Chen, Zhengjun Zhou, Jin Gu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuhao Zhao *Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Jingyun Zhang *Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Chen Zhou *School of Materials Science and Engineering East China University of Science and Technology, Shanghai, 200237, China.
Mao Yang *Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Zhigang Zheng *Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Yixiang GuDepartment of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Yang ZhangDepartment of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Xingqi ChenDepartment of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, 563003, Guizhou, China.
Zhengjun ZhouDepartment of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, 563003, Guizhou, China.
Jin GuDepartment of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, 563003, Guizhou, China.
Lijin ZhaoDepartment of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, 563003, Guizhou, China.
Wenguang WuDepartment of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. wuwenguang08@126.com.
Meidong LangSchool of Materials Science and Engineering East China University of Science and Technology, Shanghai, 200237, China. mdlang@ecust.edu.cn.
Yingbin LiuDepartment of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. laoniulyb@shsmu.edu.cn.

Funding

Guizhou Provincial Science and Technology Projects No. Qiankeherencai XKBF [2025]025the National Clinical Key Specialty Construction Project 10000015Z155080000004the National Natural Science Foundation of China No. 32130036the National Natural Science Foundation of China No. 82504141
6 · The paper itself

Abstract

Gallbladder cancer (GBC) is a highly aggressive malignancy, and its robust antioxidant defense system frequently leads to profound therapeutic resistance. Targeted disruption of redox homeostasis offers a potential strategy to overcome such resistance. In this study, we developed ICFe@D, a supramolecular nanomedicine co-assembled from iso-liquiritigenin (ISL), Fe³⁺, and chlorin e6 (Ce6) within a DSPE-PEG matrix, to trigger combined ferroptosis and apoptosis. As a tumor microenvironment (TME)-responsive platform, ICFe@D systematically dismantles the antioxidant defenses of GBC cells through a "supply-and-exhaust" mechanism. Specifically, Fe

Indexed as

FerroptosisGallbladder NeoplasmsOxidative StressAnimalsAntineoplastic AgentsAntioxidantsCell Line, TumorChlorophyllidesFemaleHumansIronMicePorphyrinsReactive Oxygen SpeciesTumor MicroenvironmentAntineoplastic AgentsAntioxidantsChlorophyllidesIronphytochlorinPorphyrinsReactive Oxygen SpeciesFerroptosisGallbladder cancerOrganoidOxidative stress amplificationSupramolecular self-assembly

Identifiers

PMID42226197
PMCPMC13439993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.